Humana's 1.54% Rally on 193rd-Ranked $440M Volume Showcases Value-Based Care Gains

On August 21, 2025, Humana (NYSE: HUM) closed with a 1.54% gain, trading on a volume of $0.44 billion, ranking 193rd in terms of trading activity among listed stocks. The healthcare insurer released new research highlighting the efficacy of its value-based care model in improving outcomes for Medicare Advantage patients with heart failure. The study revealed patients treated under this model were 28% more likely to receive full quadruple therapy—a gold standard treatment for heart failure with reduced ejection fraction (HFrEF)—compared to those in traditional care settings.

Humana emphasized that its value-based approach fosters coordinated care among primary care physicians, specialists, and patients, incentivizing high-value interventions. This contrasts with the fragmented nature of traditional fee-for-service models, which lack incentives to reduce low-value care. The findings align with over a decade of research showing value-based care leads to better chronic disease management, higher patient satisfaction, and more frequent primary care visits. Dr. Kate Goodrich, Humana’s Chief Medical Officer, underscored the model’s role in delivering proactive, holistic care for seniors post-hospitalization.

The results reinforce Humana’s strategic focus on transitioning to value-based care, a shift expected to enhance its competitive positioning in the Medicare Advantage market. Analysts note that improved health outcomes could drive long-term cost savings by reducing hospital readmissions and emergency visits, potentially attracting more enrollees and boosting revenue. With heart failure cases projected to rise to 11.4 million by 2050, the company’s emphasis on evidence-based medical practices positions it to address growing demand for chronic disease management solutions.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The CAGR was 6.98%, with a maximum drawdown of 15.59% during the backtest period. The strategy demonstrated steady growth over time, making it a robust choice for investors seeking consistent returns. However, the significant drawdown in mid-2023 highlights the importance of risk management, even in a seemingly stable strategy like this one.